Pharmacological research
A gut-liver lipid flux checkpoint mediates FAHFA protection from MASLD.
Hao Xie, Hong Sheng Cheng, Jia Xun Jarryl Ng, Shuang Zhang, Joseph Han Sol Kim, Soon Heng Tan, Choon-Hong Tan, Nguan Soon Tan
Published: 202610.1016/j.phrs.2025.108085
Abstract
Pharmacotherapies for metabolic dysfunction-associated steatotic liver disease (MASLD) remain limited. Although resmetirom and semaglutide have approvals for MASH, gut-liver axis options are still needed. Fatty Acid Esters of Hydroxy Fatty Acids (FAH…
Preview only. Read the full abstract at the source